康希諾生物(06185.HK):接種兩針滅活再打腺病毒載體疫苗加強 抗體升高78倍
據康希諾生物(06185.HK)微信公眾號消息,臨床試驗結果表明,用康希諾生物腺病毒載體新冠疫苗進行加強後,表現出良好的安全性且未發現疫苗相關的嚴重不良反應。研究人員給志願者接種兩針滅活疫苗後,再接種一針腺病毒載體新冠疫苗作為加強,14天後中和抗體GMTs為197.4 (167.7, 232.4),抗體水平升高約78倍;若第三針用滅活疫苗進行加強,抗體水平為33.6 (28.3, 39.8),升高約15.2倍。該數據表明,序貫加強後產生的中和抗體增長水平顯著優於同源加強的效果。
上述研究結果來自江蘇省疾病預防控制中心副主任朱鳳才團隊與北京生物技術研究所、東南大學等合作單位在醫學生物類論文預印本平台medRvix上發表的學術論文。朱鳳才團隊於2021年5月發起新冠疫苗序貫接種臨床研究,主要研究新型冠狀病毒滅活疫苗(Vero細胞)和重組新型冠狀病毒疫苗(5型腺病毒載體)序貫接種在中國18-59歲健康成年人中的安全性和免疫原性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.